Alzamend Neuro Inc. (ALZN)
ALZN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ALZN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001677077 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors create substantial doubt about the Company's ability to continue as a going concern ." | 10-Q 2026-09-10 |
| Cash and burn | $7.6M cash; operating cash flow -$1.7M a quarter. | Report 2026-07-31 |
| Shares outstanding | 4,825,723 (2026-09-10); 3,139,861 a year earlier; 96,940,124 three years earlier. 3y figure adjusted for splits (1-for-1350 overall). | Cover page 2026-09-10 |
| Reverse splits, 3 years | 2; latest 1-for-9 on 2025-05-12 | Source 2025-05-12 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-03-06 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-03-20 |
| Auditor | Haskell & White LLP, Irvine, California, United States | PCAOB Form AP 2026-07-28 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $110K, sold $949K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-07-31 | Not filed | -$3.0M | -$1.1M | $7.6M | No debt tags | Needs four quarters | 10-Q 2026-09-10 |
| Q4 2026 2026-04-30 | Not filed | -$2.9M | -$2.8M | $711K | No debt tags | Needs four quarters | 10-K 2026-07-22 |
| Q3 2026 2026-01-31 | Not filed | -$2.2M | -$1.7M | $2.7M | No debt tags | Needs four quarters | 10-Q 2026-03-11 |
| Q2 2026 2025-10-31 | Not filed | -$1.0M | -$1.2M | $4.4M | No debt tags | Needs four quarters | 10-Q 2025-12-09 |
| Q1 2026 2025-07-31 | Not filed | -$2.7M | -$2.4M | $5.6M | No debt tags | Needs four quarters | 10-Q 2026-09-10 |
| Q4 2025 2025-04-30 | Not filed | -$1.1M | -$689K | $3.9M | No debt tags | Needs four quarters | 10-K 2026-07-22 |
| Q3 2025 2025-01-31 | Not filed | -$1.0M | -$1.4M | $3.4M | No debt tags | Needs four quarters | 10-Q 2026-03-11 |
| Q2 2025 2024-10-31 | Not filed | -$1.4M | -$3.4M | $4.1M | No debt tags | Needs four quarters | 10-Q 2025-12-09 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-1 | 2026-08-21 |
| Latest annual report | 10-K | 2026-07-22 |
| Latest quarterly / interim | 10-Q | 2026-09-10 |
| Latest current report | 8-K/A | 2026-11-10 |
| Latest proxy | PRE 14A | 2026-08-28 |
Source: SEC EDGAR submissions feed, 398 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -12.1% |
| 1 month | -8.1% |
| 3 months | -15.1% |
| Year to date | -31.9% |
| 1 year | -46.8% |
| From 52-week high | -49.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ACXP | Acurx Pharmaceuticals Inc. | $0.9350 | -2.60% | $5.7M |
| BLRX | BioLineRx Ltd. | $1.15 | -12.61% | $5.7M |
| APRE | Aprea Therapeutics Inc. | $0.4063 | -2.38% | $5.8M |
| LTRN | Lantern Pharma Inc. | $0.3890 | -10.18% | $5.8M |
| FBLG | FibroBiologics Inc. | $0.9034 | -2.00% | $6.1M |
| JAGX | Jaguar Health Inc. | $0.3864 | -7.74% | $5.2M |
| CNSP | CNS Pharmaceuticals Inc. | $3.48 | +20.42% | $5.1M |
| TOVX | Theriva Biologics Inc. | $0.1400 | -2.85% | $6.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier